Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
PHARMACEUTICAL PREPARATIONS
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is listed on Nasdaq, where it has traded since April 5, 2024.
- Listed On
- Nasdaq
- Listed Since
- April 5, 2024
- Employees
- 51
- Market Cap
- $473M
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 99 institutions reported holding CTNM, with 30.5 million shares worth $500.6 million in aggregate. The largest reported holder was Suvretta Capital Management, with 2.8 million shares worth $46.6 million. Of the 5 largest holders listed below, 1 opened a new position in CTNM, 1 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Suvretta Capital Management | 2,841,334 | $47M | Unchanged |
| Jupiter Topco | 2,734,836 | $45M | New position |
| BlackRock | 2,064,345 | $34M | Added 208.52% |
| Johnson & Johnson | 1,979,173 | $32M | Unchanged |
| Franklin Resources | 1,839,227 | $30M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CTNM?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is listed on Nasdaq, where it has traded since April 5, 2024.
Who are the largest institutional holders of CTNM?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CTNM were Suvretta Capital Management, Jupiter Topco and BlackRock.
How many institutions own CTNM?
99 institutions reported a position in CTNM for the quarter ended June 30, 2026, worth $500.6 million in total.
Did institutions buy or sell CTNM last quarter?
Of the 5 largest reported holders, 1 opened a new position in CTNM, 1 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CTNM.
Every reported institutional holder, plus insider and congressional trades in CTNM, on SentiSense.